SCL Science Inc.
Founded in 2010 and KOSDAQ-listed in 2019, SCL Science operates medical sealant, bio-logistics, and data platform businesses.
As of 2026-10-08, SCL Science Inc. has 10 Korean MFDS device approvals, 5 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in April 2010 and listed on KOSDAQ in February 2019, SCL Science is a medical device company operating a medical sealant business built on hemostasis and sealing protein-binding platforms, a bio-logistics business, and a data platform business. Its hemostasis platform products include InnoSEAL, InnoLOCK, InTro, and InnoSEAL Plus DL, while its data platform business offers the AI imaging-reading solution HiImage and the health-checkup management solution MyOneCare. Consolidated revenue for the 16th fiscal term (2025) reached KRW 22,011 million, up 365% from KRW 4,737 million the prior year, driven mainly by the consolidation of wholly owned subsidiary SCL Healthcare (acquired March 2025) and the medical diagnostics business unit (acquired July 2025).
Products & technology
- InnoSEAL Hemostatic PadTopical hemostatic dressing used in vascular intervention procedures
- InnoLOCK Hemostasis ValveNon-implantable vascular access device
- InnoSEAL Radial Band2Hemostasis band/tourniquet
- InTroIntravascular guiding catheter
- InnoSEAL Plus DLAbsorbable internal hemostatic agent used for hemostasis in intra-abdominal surgeries such as liver resection
- HiImageAI-based solution supporting physicians in reading X-ray and CT images
- MyOneCareIntegrated health checkup management solution
- Bio-logistics serviceIoT-based cold-chain transport service for temperature/time-sensitive human-derived materials, biological products, pharmaceuticals, and medical devices
Regulatory approvals
data.go.kr10 Korean MFDS device approvals · 2015–2025
- MFDSDressing, collagen, wound2025-05-28Product approval · Class 3제허 25-354 호
- MFDSHemostat, internal, absorbable2025-02-03Product approval · Class 4제허 25-61 호
- MFDSIntravascular guiding catheter2024-05-29Product approval · Class 2제인 24-536 호
- MFDSDressing, topical hemostasis, external2022-11-23Product approval · Class 2제인 22-4906 호
- MFDSHemostat, internal, absorbable2022-03-28Product approval · Class 4제허 22-210 호
- MFDSDressing, topical hemostasis, externalRevoked2022-01-13Product approval · Class 2제인 22-4019 호
- MFDSTourniquet strapRevoked2020-07-31Product approval · Class 1제신 20-1164 호
- MFDSHemostat, internal, absorbable2019-12-24Product approval · Class 4제허 19-832 호
- MFDSHemostat, internal, absorbable2019-10-08Product approval · Class 4제허 19-633 호
- MFDSDressing, topical hemostasis, external2015-03-04Product approval · Class 2제인 15-311 호
R&D and key agreements
Source: DART corporate disclosure밀폐 플랫폼 · 각종 천공 부위의 체액 누출 방지 · 개발 중 · Developing a sealing platform to prevent fluid leakage from various perforation sites.
Key disclosures
KRX KIND via OpenDARTShow 7 more events
Publications
PubMed · affiliation-matched- Flexible Catechol-Conjugated Chitosan/Gelatin Bilayer Patches for Topical Hemostasis in Laparoscopic Surgery.
ACS omega · 2026-09 · Kim SA, Shin HH, Lee JY 외 6
- Bioinspired Injectable Thermosensitive Gallic Acid-Conjugated Hyaluronic Acid/Pluronic Hydrogels to Prevent Postoperative Adhesion.
Biomimetics (Basel, Switzerland) · 2026-09 · Lee JY, Shin HH, Jo S 외 2
- SIGMA: Shear-induced gelation by microbead aggregation in tubular flow systems.
Materials today. Bio · 2026-06 · Nam YR, Lee Y, Kim K 외 4
- Efficacy and Safety of a Bioinspired Chitosan-Catechol/Gelatin Hemostatic Patch vs. TachoSil in Hepatectomy: A Randomized Noninferiority Trial.
Biomedicines · 2026-05 · Kim SH, Kim K, Yun K 외 1
- rev-Gelatin: A Gelatin with Reverse Thermo-Responsive Behavior Inspired by Candy and Ice Cubes Phase Dynamics.
Macromolecular bioscience · 2025-12 · Lee Y, Nam YR, Kim K 외 6
Patents
KIPRIS · applicant-matched- Subsidiary: (주)에스씨엘헬스케어NON-INVASIVE PRENATAL TESTING METHOD CAPABLE OF SIMULTANEOUSLY DIAGNOSING ANEUPLOIDIES OF AUTOSOMAL CHROMOSOMES AND SEX CHROMOSOMES
PCT · Published · 2025-03 · Application PCT/KR2025/099682
PCT · Published · 2024-11 · Application PCT/KR2024/017192
PCT · Published · 2024-10 · Application PCT/KR2024/016758
- Subsidiary: (주)에스씨엘헬스케어EPIGENETIC METHYLATION MARKER FOR PREDICTING METABOLIC SYNDROME, AND KIT USING SAME
EP · Published · 2024-09 · Application 24872849.5
- Subsidiary: (주)에스씨엘헬스케어EPIGENETIC METHYLATION MARKER FOR PREDICTING METABOLIC SYNDROME, AND KIT USING SAME
PCT · Published · 2024-09 · Application PCT/KR2024/014347
- Subsidiary: (주)에스씨엘헬스케어상염색체 및 성염색체의 이수성을 동시에 진단 가능한 비침습적 산전 검사 방법
Registered · 2024-03 · Application 1020240034946
- Subsidiary: (주)에스씨엘헬스케어대사증후군 예측용 후성유전 메틸화 마커, 및 이를 이용한 키트
Registered · 2024-01 · Application 1020240009354
- Subsidiary: (주)에스씨엘헬스케어대사증후군 예측용 후성유전 메틸화 마커, 및 이를 이용한 키트
Registered · 2024-01 · Application 1020240009338
- Subsidiary: (주)에스씨엘헬스케어대사증후군 예측용 후성유전 메틸화 마커, 및 이를 이용한 키트
Registered · 2024-01 · Application 1020240009350
Registered · 2023-12 · Application 1020230181593
Show 41 more patents
- Subsidiary: (주)에스씨엘헬스케어수면장애 예측용 바이오마커, 및 이를 이용한 수면장애 예측 방법
Registered · 2023-12 · Application 1020230174076
Registered · 2023-10 · Application 1020230147561
- Subsidiary: (주)에스씨엘헬스케어대사증후군 예측용 후성유전 메틸화 마커, 및 이를 이용한 키트
Registered · 2023-09 · Application 1020230127796
- Subsidiary: (주)에스씨엘헬스케어GENETIC VARIATION ANALYSIS METHOD BASED ON NUCLEIC ACID SEQUENCING
US · Published · 2023-02 · Application 18837108
- Subsidiary: (주)에스씨엘헬스케어GENETIC VARIATION ANALYSIS METHOD BASED ON NUCLEIC ACID SEQUENCING
EP · Published · 2023-02 · Application 23756665.8
- Subsidiary: (주)에스씨엘헬스케어GENETIC VARIATION ANALYSIS METHOD BASED ON NUCLEIC ACID SEQUENCING
PCT · Published · 2023-02 · Application PCT/KR2023/002310
- Subsidiary: (주)에스씨엘헬스케어습관성 유산 예측용 바이오마커
Registered · 2022-12 · Application 1020220179009
Registered · 2022-11 · Application 1020220150346
- Subsidiary: (주)에스씨엘헬스케어핵산서열 분석 기반 유전자 변이 해석 방법
Registered · 2022-02 · Application 1020220020483
- Subsidiary: (주)에스씨엘헬스케어COMPOSITION FOR DIAGNOSING OR PREDICTING METABOLIC SYNDROME
PCT · Published · 2022-01 · Application PCT/KR2022/000371
- Subsidiary: (주)에스씨엘헬스케어Composition for diagnosis or prediction of metabolic syndrome or group at high risk of expression of blood ceramide
US · Registered · 2021-09 · Application 18248133
- Subsidiary: (주)에스씨엘헬스케어COMPOSITION FOR DIAGNOSIS OR PREDICTION OF METABOLIC SYNDROME OR GROUP AT HIGH RISK OF EXPRESSION OF BLOOD CERAMIDE
PCT · Published · 2021-09 · Application PCT/KR2021/012700
Registered · 2021-02 · Application 1020210015100
- Subsidiary: (주)에스씨엘헬스케어대사증후군 진단 또는 예측용 조성물
Registered · 2021-01 · Application 1020210004787
- Subsidiary: (주)에스씨엘헬스케어Primer group for analyzing HIV-1 (human immunodeficiency virus-1) drug resistance, kit comprising primer group and analysis method using primer group
CN · Published · 2020-12 · Application 202080096567.7
- Subsidiary: (주)에스씨엘헬스케어PRIMER SET FOR ANALYZING HIV-1 DRUG RESISTANCE, KIT COMPRISING SAME, AND ANAYSIS METHOD USING SAME
US · Published · 2020-12 · Application 17799654
- Subsidiary: (주)에스씨엘헬스케어PRIMER SET FOR ANALYZING HIV-1 DRUG RESISTANCE, KIT COMPRISING SAME, AND ANAYSIS METHOD USING SAME
PCT · Published · 2020-12 · Application PCT/KR2020/018471
Registered · 2020-10 · Application 1020200139090
- Subsidiary: (주)에스씨엘헬스케어대사증후군 또는 혈중 세라마이드 고발현 위험군 진단 또는 예측용 조성물
Registered · 2020-10 · Application 1020200128464
Expired · 2020-04 · Application 1020200047768
Registered · 2020-03 · Application 1020200025776
- Subsidiary: (주)에스씨엘헬스케어HIV-1 약제 내성 분석을 위한 프라이머 세트, 이를 포함하는 키트, 및 이를 이용한 분석 방법
Registered · 2020-02 · Application 1020200017771
Registered · 2020-02 · Application 1020200015744
Rejected · 2019-11 · Application 1020190150070
- Subsidiary: (주)에스씨엘헬스케어대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
Registered · 2019-10 · Application 1020190122254
- Subsidiary: (주)에스씨엘헬스케어대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
Registered · 2019-10 · Application 1020190122249
- Subsidiary: (주)에스씨엘헬스케어대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
Registered · 2019-10 · Application 1020190122258
- Subsidiary: (주)에스씨엘헬스케어대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
Registered · 2019-10 · Application 1020190122264
- Subsidiary: (주)에스씨엘헬스케어비알콜성 지방간증을 동반한 대사증후군 예측용 단일염기다형성 및 이의 용도
Registered · 2019-06 · Application 1020190066134
- Subsidiary: (주)에스씨엘헬스케어대사증후군의 위험인자 예측용 단일염기다형성 및 이의 용도
Registered · 2019-01 · Application 1020190012632
Expired · 2018-07 · Application 1020180080237
- Subsidiary: (주)에스씨엘헬스케어민감도 및 특이성이 향상된 지방산 분석 방법
Rejected · 2017-03 · Application 1020170027413
Expired · 2016-09 · Application 1020160122060
Registered · 2015-04 · Application 1020150047329
Rejected · 2014-12 · Application 1020140184663
Registered · 2013-12 · Application 1020130164490
Rejected · 2013-02 · Application 1020130018719
Expired · 2013-02 · Application 1020130013557
Expired · 2011-11 · Application 1020110121482
Expired · 2011-05 · Application 1020110050019
Expired · 2010-09 · Application 1020100090232
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot53
- GoogleGoogleOther2
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 25, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SCL Science Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
Founded in 1991 and KOSDAQ-listed in 2003, Autech Corporation manufactures specialty vehicles such as ambulances and refrigerated trucks.
Founded in 2013 and KOSDAQ-listed in 2018, T&R Biofab commercializes 3D bioprinting systems, bioinks, and biodegradable scaffolds.
Founded and KOSDAQ-listed in 2018, WSI distributes spine/joint devices and has expanded into medical robots and pharma via subsidiaries.
Founded in 2004 and listed on KOSDAQ in 2011, NIBEC develops dental tissue regeneration biomaterials and peptide-based biomaterials.
Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.
Interojo, founded 2000 and KOSDAQ-listed 2010, manufactures contact lenses under its Clalen brand domestically and via OEM/ODM overseas.
MITECH CO.,LTD., founded in 1991 and listed on KOSDAQ in 2018, makes non-vascular stents and distributes Fujifilm endoscopy equipment.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition